CTMX CytomX Therapeutics, Inc.

XNAS 2.05 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CTMX $2.05 —
Key stats
$2.05
52-Week Range
$1.87 – $8.21
YTD
-51.78%
IV Rank (30D)
61.85
Straddle Price
$0.48
P/C Vol Ratio
0.44
Market Cap
$0.4B
Open
$1.88
Day Range
$1.87 – $2.06
Volume
4,055,722
Prev Close
$1.88
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.41
Cost of Equity (CAPM)12.85% (VRP-adj)
WACC12.76%
Volatility Risk Premium+91.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-31.0%
Book / Price69.2% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-363.6%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$2.46 (Market Anchor value)
SMA 20 / Bollinger Mid$2.17
Bollinger Width / SMA2029.6% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
94%
20-Day Fair Value
≈ by Dec 18, 2026
$2.04
α -0.1% rank 70%
conviction
11%
40-Day Fair Value
≈ by Jan 18, 2027
$2.07
α +1.4% rank 68%
conviction
77%
60-Day Fair Value
≈ by Feb 16, 2027
$2.13
α +4.0% rank 67%
conviction
94%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 40.2× · 3 peers
Peer EV/EBITDA n/a 0% median 19.7× · 3 peers
Peer P/B $4.62 19% median 3.5× · 3 peers
Peer P/S $0.26 19% median 3.8× · 3 peers
Market Anchor (SMA50) $2.46 63% stability 65% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.4B
Employees
69
List Date
2015-10-08
CIK
0001501989
Last Earnings
Nov 5 after close · +2.3% vs ±23.4% expected
Headquarters
South San Francisco, CA
Homepage
https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan1.92%2.45%67.70%-9.47%-19.81%33.88%12.78%
Feb3.70%-18.16%-19.78%60.13%-19.39%-11.82%-0.89%
Mar-8.52%-24.58%-30.41%-17.74%-2.23%-11.99%-15.91%
Apr18.93%-39.15%5.84%-24.19%28.33%-7.46%-2.95%
May-24.63%-11.54%-0.58%-66.86%249.93%-13.88%22.07%
Jun-7.66%18.06%2.38%-30.29%-9.56%8.70%-3.06%
Jul-15.86%-22.28%-2.25%3.76%-7.20%-14.84%-9.78%
Aug-8.73%5.63%-11.24%-11.94%-13.19%5.99%-5.58%
Sep-2.12%-3.97%-14.00%5.36%53.37%-25.89%2.12%
Oct16.05%-12.08%-12.00%-13.42%6.57%-11.03%-4.32%
Nov16.37%32.82%28.70%0.95%8.91%-7.85%*13.32%
Dec-35.37%-6.43%9.93%-5.50%-0.70%---7.61%
Total-47.50%-65.38%-6.31%-83.39%265.51%-50.64%2.05%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.15
SMA 50: $2.44
SMA 200: $3.63
Current: $2.04
EMA 12: $2.06
EMA 26: $2.20
MACD: -0.1459 | Signal: 0.0018
BEARISH
ADX (14): 23.28
WEAK TREND
+DI: 13.73
−DI: 18.18

Momentum Oscillators

RSI (14): 42.90
NEUTRAL
Stoch %K: 14.42
Stoch %D: 13.35
Williams %R: -66.35

Volume & Volatility

BB Upper: $2.45
BB Lower: $1.85
NEUTRAL
OBV: 217,037,843
Vol SMA 20: 5,335,972
Vol ROC: 4.53%
ATR: $0.18
True Range: $0.19
HV 20: 81.8%
HV 30: 81.4%
HV 60: 76.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before CTMX’s Nov 5 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

SYMBOL: CTMX CURRENT PRICE: $3.44

Executive Summary Overall assessment: BEARISH (confidence level 6/10) Key drivers:

  • MACD bearish signal
  • Volatility indicators suggest high risk
  • Beta above market average Primary risks:
  • Potential for further price decline due to negative sentiment and technical signals
  • High volatility may lead to increased trading activity, amplifying price movements

Recent news sentiment impact: Positive news headlines have had a mixed impact on the stock's price, with some headlines highlighting collaborations and research initiatives, while others focus on company announcements. The overall positive sentiment has been tempered by the bearish MACD signal.

Technical Analysis Trend direction:

  • Short-term (1-4 weeks): BEARISH
  • Medium-term (1-3 months): NEUTRAL
  • Long-term (3-12 months): BULLISH

Support/resistance levels:

  • Upper: $3.76 (Bollinger Bands upper band)
  • Middle: $3.39 (SMA 50 and EMA 12)
  • Lower: $3.02 (Bollinger Bands lower band)

Momentum signals:

  • RSI: NEUTRAL (52.35) - not indicating overbought or oversold conditions
  • MACD: BEARISH signal (-0.05 / Signal: 0.01 / Histogram: -0.06)
  • Bollinger Bands: NEUTRAL - price within the middle band

Volume analysis:

  • Volume SMA 20: 2974791.00 (high volume trend)
  • On-Balance Volume (OBV): 250765665.63 (positive volume trend)
  • Volume Rate of Change: 17.31% (increasing volume trend)

News & Sentiment Analysis Recent headlines summary:

  • Positive news highlights company collaborations and research initiatives
  • Neutral news focuses on company announcements

Sentiment assessment:

  • Aggregate sentiment: POSITIVE (due to recent positive headlines)

Catalyst identification:

  • Upcoming investor conferences (June) - potential for new information or insights

Market narrative:

  • News aligns with technical signals, indicating a potentially bearish market sentiment

Risk & Volatility Assessment Beta interpretation:

  • Beta above market average (1.59 vs SPY) - high risk

Volatility regime:

  • Current volatility higher than historical levels (0.93)

Options market signals:

  • IV rank: 15.9% (Low)
  • Put/call ratio: 0.01 (Bullish sentiment)

Downside protection:

  • Support level: $3.02 (Bollinger Bands lower band)

Market Context & Positioning Sector performance:

  • Healthcare sector performing strongly

Institutional activity:

  • High volume trend suggests institutional interest

Correlation analysis:

  • Stock moves more than market (high correlation, 0.22) - high risk

Relative valuation:

  • Position within trading range - potentially oversold or overbought

Key Levels & Action Items Critical price levels:

  • Support: $3.02 (Bollinger Bands lower band)
  • Resistance: $3.76 (Bollinger Bands upper band)

Breakout/breakdown levels:

  • Breakout above $3.76 could trigger a bullish move
  • Breakdown below $3.02 could lead to further price decline

Time-sensitive catalysts:

  • Upcoming investor conferences (June) - potential for new information or insights

Risk management:

  • Stop-loss level: $3.20 (below the current price)
  • Position sizing considerations: 50% cash reserve, 50% invested
Generated
Earnings History
16 of 16 under expected move
Avg Expected Move
50.53%
Avg Actual Move
12.86%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-19 After-Close 26.30% 3.83% 0.15x Within
2021-05-06 After-Close 18.90% 4.91% 0.26x Within
2021-11-04 After-Close 47.66% 10.37% 0.22x Within
2022-03-01 After-Close 52.26% 14.12% 0.27x Within
2023-08-08 After-Close 48.52% 3.55% 0.07x Within
2024-03-11 After-Close 21.91% 14.34% 0.65x Within
2024-05-08 After-Close 85.44% 51.31% 0.60x Within
2024-08-08 After-Close 252.12% 1.69% 0.01x Within
2024-11-07 After-Close 55.00% 9.00% 0.16x Within
2025-05-12 After-Close 17.61% 17.37% 0.99x Within
2025-08-07 After-Close 32.14% 11.90% 0.37x Within
2025-11-06 After-Close 29.24% 13.60% 0.47x Within
2026-03-16 Pre-Market 68.91% 44.23% 0.64x Within
2026-05-07 After-Close 10.63% 0.50% 0.05x Within
2026-08-06 After-Close 18.55% 2.67% 0.14x Within
2026-11-05 After-Close 23.36% 2.34% 0.10x Within

Earnings calendar: this week’s reports with expected vs actual moves →

CTMX Options Activity & IV Rank

CTMX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 165.3%
7-DTE IV: —
Expected Move: $0.48
7-DTE Move: $0.55
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 1,184
Put Volume: 519
P/C Volume: 0.438
BULLISH
Call OI: 14,629
Put OI: 6,254
P/C OI: 0.428
Total OI: 20,883

ATM Options Pricing

ATM Call: $0.28
ATM Put: $0.20
Call %: 13.4%
Put %: 9.8%

Chain Summary

Chain Volume: 1,703
Chain OI: 20,883
Last Updated: 11/19/2026

CTMX Implied Volatility

30-day IV
165.3%
Nov 19
IV rank
62Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much CTMX actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 90th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
90%
vs own history
GEX tilt
+0.96
OI-weighted, today
Vanna tilt
+0.00
δ-sensitivity to IV
Charm tilt
+0.99
δ-decay vs time
Charm tilt +0.99: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 5 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 112.2% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)61.9MediumNov 19

Embed CTMX IV rank

CTMX's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$0.48Nov 19
Beta Analysis

Risk Metrics

Beta: 1.4463
Alpha: -35.72%
Correlation: 0.2355
R-Squared: 5.5%
Stock Volatility: 85.3%
Market Volatility: 13.9%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CTMX
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$29.3M
0.04%
#474 of 1945-0.8%13F
Citadel Hedge fund
Ken Griffin
$11.7M
0.01%
#1467 of 6285-42.5%13F
Millennium Management Hedge fund
Izzy Englander
$6.3M
0.00%
#1905 of 3716-53.9%13F
Rockefeller Capital Management Family office
Rockefeller family
$3K
0.00%
#4508 of 4858new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CTMX Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 196,458,015 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

194 filers218,758,105 shares$739.52M value111.35% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 32,714,937 $122.68M 16.59% 16.65% 2026-06-30
2 Kynam Capital Management, LP 21,703,093 $81.39M 11.01% 11.05% 2026-06-30
3 Bank of America Corp Custodian 15,082,617 $56.56M 7.65% 7.68% 2026-06-30
4 BlackRock, Inc. Custodian 18,470,807 $50.24M 6.79% 9.40% 2026-09-30
5 PERCEPTIVE ADVISORS LLC 10,439,185 $39.15M 5.29% 5.31% 2026-06-30
6 Point72 Asset Management, L.P. 7,811,033 $29.29M 3.96% 3.98% 2026-06-30
7 State Street Corp 9,025,855 $24.55M 3.32% 4.59% 2026-09-30
8 Vanguard Capital Management LLC 8,732,337 $23.75M 3.21% 4.44% 2026-09-30
9 Wellington Management Group LLP Custodian 5,168,961 $19.38M 2.62% 2.63% 2026-06-30
10 Venrock Adviser, LLC 4,982,124 $18.68M 2.53% 2.54% 2026-06-30
11 BAKER BROS. ADVISORS LP 4,975,826 $18.66M 2.52% 2.53% 2026-06-30
12 Elmind Capital, LP 4,550,000 $17.06M 2.31% 2.32% 2026-06-30
13 Nextech Invest Ltd. 4,449,932 $16.69M 2.26% 2.27% 2026-06-30
14 Two Sigma Investments, LP Custodian 4,132,643 $15.50M 2.10% 2.10% 2026-06-30
15 Geode Capital Management, LLC Custodian 5,093,451 $13.86M 1.87% 2.59% 2026-09-30
16 Eversept Partners, LP 3,558,497 $13.34M 1.80% 1.81% 2026-06-30
17 Marshall Wace, LLP Custodian 4,362,687 $11.87M 1.60% 2.22% 2026-09-30
18 Citadel Advisors LLC Custodian 3,110,509 $11.66M 1.58% 1.58% 2026-06-30
19 Qube Research & Technologies Ltd 4,187,989 $11.39M 1.54% 2.13% 2026-09-30
20 Siren, L.L.C. 3,457,711 $9.40M 1.27% 1.76% 2026-09-30
21 UBS Group AG Custodian 3,437,209 $9.35M 1.26% 1.75% 2026-09-30
22 Woodline Partners LP 2,040,210 $7.65M 1.03% 1.04% 2026-06-30
23 Goldman Sachs Group Inc Custodian 2,003,652 $7.51M 1.02% 1.02% 2026-06-30
24 Millennium Management LLC Custodian 1,685,830 $6.32M 0.85% 0.86% 2026-06-30
25 Northern Trust Corp Custodian 1,675,183 $6.28M 0.85% 0.85% 2026-06-30
7 filers$4.94M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $2.62M 53.19% 2026-06-30
2 Susquehanna International Group, LLP Custodian $1.40M 28.27% 2026-06-30
3 Citadel Advisors LLC Custodian $491.25K 9.95% 2026-06-30
4 TUDOR INVESTMENT CORP ET AL $188.62K 3.82% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $149.60K 3.03% 2026-09-30
6 Jane Street Group, LLC Custodian $60.38K 1.22% 2026-09-30
7 Simplex Trading, LLC Custodian $25.30K 0.51% 2026-09-30
5 filers$2.32M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $1.57M 68.02% 2026-06-30
2 Citadel Advisors LLC Custodian $332.25K 14.35% 2026-06-30
3 Susquehanna International Group, LLP Custodian $307.12K 13.26% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $53.04K 2.29% 2026-09-30
5 Simplex Trading, LLC Custodian $48.14K 2.08% 2026-09-30

CTMX Insider Trading (Form 4)

Latest: 2026-10-16
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-16 Sean A. McCarthy CEO Mixed
Sell −101,793 · Exer +101,793
— $3.06 -$300.1K EDGAR
2026-08-05 Alejandra Carvajal Chief Legal Officer Award (A) +100,000 — EDGAR
2026-07-30 Charles S. Fuchs Director Grant (A) +118,000 opt — EDGAR
2026-06-22 Halley E Gilbert Director Grant (A) +59,000 opt — EDGAR
2026-06-22 James R Meyers Director Grant (A) +59,000 opt — EDGAR
2026-06-22 Matthew P. Young Director Grant (A) +59,000 opt — EDGAR
2026-06-22 Mani Mohindru Director Grant (A) +59,000 opt — EDGAR
2026-06-22 Alan Ashworth Director Grant (A) +59,000 opt — EDGAR
2026-06-22 Zhen Su Director Grant (A) +59,000 opt — EDGAR
2026-06-22 Elaine V Jones Director Grant (A) +59,000 opt — EDGAR
2026-06-17 Christopher Ogden Chief Financial Officer Sell (S) −1,624 $3.05 -$5.0K EDGAR
2026-03-19 Christopher Ogden Chief Financial Officer Sell (S) −19,323 $6.42 -$124.1K EDGAR
2026-03-19 Yu-Waye Chu Chief Medical Officer Sell (S) −21,279 $6.42 -$136.7K EDGAR
2026-03-19 Sean A. McCarthy CEO Sell (S) −118,969 $6.42 -$764.1K EDGAR
2026-03-19 Marcia Belvin SVP, Chief Scientific Officer Sell (S) −31,492 $6.42 -$202.3K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CTMX Insider Holdings

8 insiders · @ $2.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Sean A. McCarthy CEO 1,284,635 $2.63M -$9.41M 71 2026-10-16
2 Marcia Belvin SVP, Chief Scientific Officer 300,760 $615.1K -$294.1K 14 2026-03-19
3 Christopher Ogden Chief Financial Officer 295,324 $603.9K -$180.0K 16 2026-06-17
4 Yu-Waye Chu Chief Medical Officer 189,446 $387.4K -$139.1K 7 2026-03-19
5 Lloyd A Rowland General Counsel 120,594 $246.6K $46.0K 19 2025-03-20
6 Alejandra Carvajal Chief Legal Officer 100,000 $204.5K $0 1 2026-08-05
7 Rachael Lester Chief Business Officer 20,000 $40.9K $0 2 2026-02-04
8 Elaine V Jones Director 5,142 $10.5K $7.8K 10 2026-06-22
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CTMX Board & Officers

As of SEC filings through Oct 16, 2026

Directors 9

Officers 6

Changes in the last 10 years (44)
Aug 3, 2026Alejandra Carvajal became Chief Legal Officer
Oct 20, 2025Rachael Lester became Chief Business Officer
Jan 30, 2025The company announced the departure of Jeffrey B Landau as Chief Business Officer in an SEC filing
Jun 14, 2024Christopher Ogden listed as Chief Financial Officer (previously SVP, Finance and Accounting) in SEC filings
Mar 20, 2024Zhen Su became a director
Jul 19, 2023Yu-Waye Chu became Chief Medical Officer
Mar 22, 2023Marcia Belvin became SVP, Chief Scientific Officer
Aug 12, 2022Sean A. McCarthy listed as CEO (previously President and CEO) in SEC filings
Aug 12, 2022Christopher Ogden listed as SVP, Finance and Accounting (previously Interim Principal Accounting Officer) in SEC filings
Jul 13, 2022The company announced the departure of Carlos Campoy as Chief Financial Officer in an SEC filing
Jul 13, 2022The company announced the departure of Alison L. Hannah as Chief Medical Officer in an SEC filing
Apr 11, 2022The company announced the departure of John A Scarlett from the board in an SEC filing
Mar 23, 2022The company announced the departure of Frederick W Gluck from the board in an SEC filing
Mar 23, 2022Jeffrey B Landau became Chief Business Officer
Feb 14, 2022Christopher Ogden became Interim Principal Accounting Officer
Sep 29, 2021Alan Ashworth became a director
Feb 18, 2021Mark N Lampert reported in an SEC filing no longer being a 10% owner
Feb 18, 2021Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner
Feb 18, 2021Bvf Inc/il reported in an SEC filing no longer being a 10% owner
Feb 18, 2021Bvf Gp Holdings LLC reported in an SEC filing no longer being a 10% owner
Not reported recently (13)
  • Lloyd A Rowland · Last reported as General Counsel in an SEC filing dated Mar 20, 2025
  • Amy C. Peterson · Last reported as EVP, Chief Development Officer in an SEC filing dated Mar 20, 2023
  • Robin Knifsend · Last reported as Principal Accounting Officer in an SEC filing dated Feb 21, 2020
  • William Michael Kavanaugh · Last reported as CSO, Head Res.&Non-Clin. Dev. in an SEC filing dated Feb 19, 2020
  • Rachel Humphrey · Last reported as Chief Medical Officer in an SEC filing dated Jan 29, 2019
  • Debanjan Ray · Last reported as Chief Financial Officer in an SEC filing dated Jan 29, 2019
  • Hoyoung Huh · Last reported as a director in an SEC filing dated Jun 15, 2018
  • Neil Exter · Last reported as a director in an SEC filing dated Jun 22, 2017
  • Marion McCourt · Last reported as a director in an SEC filing dated Jun 22, 2017
  • Canaan IX L.P. · Last reported as a director in an SEC filing dated Mar 28, 2017
  • Canaan Partners IX LLC · Last reported as a director in an SEC filing dated Mar 28, 2017
  • Cynthia J Ladd · Last reported as Senior VP and General Counsel in an SEC filing dated Jan 27, 2017
  • Timothy M Shannon · Last reported as a director in an SEC filing dated Dec 1, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

CTMX Proposed Insider Sales (Form 144)

Latest: 2025-11-06
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2025-11-06 Sean McCarthy CEO 101,793 $461.9K 2025-11-06 Merrill Lynch 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results EDGAR
2026-08-06 Earnings results EDGAR
2026-07-27 Director or officer change EDGAR
2026-06-22 Director or officer change · Bylaws or fiscal year change · Shareholder vote results EDGAR
2026-06-03 Material agreement EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001193125-26-449739 EDGAR
2026-08-06 0001193125-26-337950 EDGAR
ETF Holders
52 ETFs hold CTMX
25 shown · $54.31M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $11.5M — 2026-10-31
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.10% $10.1M $9.7B 2026-11-17
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $9.5M $75.0B 2026-11-17
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $5.4M — 2026-10-31
5 IBB iShares Biotechnology ETF iShares (BlackRock) 0.03% $2.9M $10.9B 2026-11-17
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $2.6M — 2026-10-31
7 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.01% $1.9M $13.5B 2026-11-17
8 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $1.6M $13.6B 2026-11-17
9 VHT Vanguard Health Care ETF Vanguard 0.01% $1.2M — 2026-10-31
10 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.10% $1.1M $1.2B 2026-11-17
11 IDNA iShares Genomics Immunology and Healthcare ETF iShares (BlackRock) 0.32% $1.0M $324.6M 2026-11-17
12 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.06% $946,923 — 2026-07-31
13 CANC Tema Oncology ETF Nport 0.38% $810,892 — 2026-08-31
14 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $691,375 $93.0B 2026-11-17
15 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.08% $397,809 — 2026-11-18
16 FMED Fidelity Disruptive Medicine ETF Nport 0.73% $376,552 — 2026-08-31
17 BFOR Barrons 400 ETF Nport 0.16% $368,370 — 2026-08-31
18 BBC Virtus Biotech Clinical Trials Etf Nport 0.69% $320,103 — 2026-07-31
19 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.02% $265,190 — 2026-10-31
20 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $263,157 — 2026-11-17
21 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $257,052 — 2026-07-31
22 EES WisdomTree U.S. SmallCap Fund Nport 0.04% $254,554 — 2026-06-30
23 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.00% $183,990 $4.1B 2026-11-17
24 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $180,622 — 2026-10-31
25 RSSL Global X Russell 2000 ETF Global X 0.01% $166,705 — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.45
TTM Revenue
$14.03M
TTM Net Income
$-88.42M
TTM Op. Cash Flow
$-50.21M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$1.69M$-20.00M$-0.09$16.65M
Q2 '262026-06-30$1.42M$-20.67M$-0.09$-18.07M
Q1 '262026-03-31$10.26M$-18.25M$-0.10$-25.55M
Q4 '252025-12-31$663.00K$-29.51M$-0.17$-23.24M
Q3 '252025-09-30$5.96M$-14.23M$-0.09$-15.55M
Q2 '252025-06-30$18.66M$-154.00K—$-15.75M
Q1 '252025-03-31$50.92M$23.52M$0.27$-21.04M
Q4 '242024-12-31$38.09M$18.88M$0.23$-19.91M
Q3 '242024-09-30$33.43M$5.74M$0.07$-20.73M
Q2 '242024-06-30$25.11M$-6.53M$-0.08$-19.55M
Q1 '242024-03-31$41.46M$13.79M$0.17$-26.05M
Q4 '232023-12-31$26.61M$837.00K$0.01$-21.96M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.42
P/S
28.78
EV/EBITDA
—
EV/Sales
26.36
ROE
-31.0%
ROA
-24.2%
Div Yield
0.00%
FCF Yield
-12.44%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$403.72M
as of 2026-11-19

CTMX vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 43.9 +45.5% +25.2% 37
MRK Merck & Co., Inc. $339.7B 136.2 +4.9% +24.1% 56
MRNA Moderna, Inc. Common Stock $79.6B — +13.1% +547.8% 37
RVMD Revolution Medicines, Inc. Common Stock $34.6B — — +102.1% 68
GMAB Genmab A/S ADS $31.4B — — +60.8% 7
EXEL Exelixis Inc $16.7B 19.7 +9.1% +51.0% 36
TWST Twist Bioscience Corporation Common Stoc $7.9B — +22.0% +247.3% 51
COGT Cogent Biosciences, Inc. Common Stock $4.8B — — −19.5% 86
CTMX CytomX Therapeutics, Inc. $410M — −87.7% −51.9% 62
Peer median $33.0B 43.9 +13.1% +55.9% 44

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
45.25M
SI % of Float
23.67%
Days to Cover
11.99
Short Vol Ratio
34.5%
Free Float
191.12M
Float %
87.7%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-09-22